Publications

Clinical Highlights: April 2025

Your monthly source for drug information highlights.

April 29, 2025

Trending topics

  • Results from the double-blind, placebo-controlled SOUL trial (n=9,650) have been published in The New England Journal of Medicine. After a median follow-up of 49.5 months, oral semaglutide (Rybelsus) 14 mg daily was associated with a significantly lower risk of major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke) versus placebo (hazard ratio, 0.86; 95% confidence interval [CI], 0.77 to 0.96; p=0.006) in patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease, chronic kidney disease or both. Novo Nordisk has also announced results from the 52-week, Phase 3b STRIDE trial (n=792) in which semaglutide (Ozempic) 1 mg subcutaneous (SC) weekly demonstrated a statistically significant improvement in maximum walking distance by 13% versus placebo (p=0.0004) in adults with T2DM and symptomatic peripheral artery disease (PAD). At 52 weeks, the median treatment difference favoring semaglutide was 26.4 meters (95% CI, 11.8 to 40.9) on a 12% incline. Based on these results, Novo Nordisk has submitted a label extension application to the United States (U.S.) Food and Drug Administration (FDA) for Ozempic; a decision is expected in 2025. 

  • A multicenter, randomized, open-label, Phase 4 study (SURPASS-SWITCH; n=282), published in the Annals of Internal Medicine, evaluated adults with hemoglobin A1c (HbA1c) between 7% to ≤ 9.5%, a stable body weight and a body mass index (BMI) of ≥ 25 kg/m2 who had been receiving a stable dose of dulaglutide (0.75 mg or 1.5 mg) for at least six months and zero to three oral antihyperglycemic medications. Patients were randomized to either switch to tirzepatide or escalate the dulaglutide dose to 4.5 mg or the maximum tolerated dose (MTD). At week 40, the primary endpoint of change from baseline in HbA1c was significantly improved with switching to tirzepatide 15 mg or MTD (-1.44%) compared to escalation of dulaglutide (-0.67%) (estimated treatment difference, -0.77%; 95% CI, -0.98% to -0.56%; p<0.001). Furthermore, the key secondary endpoint of change from baseline in weight at week 40 was also significantly improved with tirzepatide (-10.5 kg) compared with dulaglutide (-3.6 kg) (estimated treatment difference, -6.9 kg; CI, -8.3 to -5.5 kg; p<0.001). 

  • A systematic review and meta-analysis published in JAMA Neurology evaluated the potential for cardioprotective glucose-lowering agents (sodium-glucose cotransporter-2 inhibitors [SGLT2is], glucagon-like peptide-1 agonists [GLP-1s], metformin and pioglitazone) to reduce the risk of dementia across 23 randomized clinical trials (n=160,191). A significant association between cardioprotective glucose-lowering therapy and decreases in cognitive impairment or dementia was not found (odds ratio [OR], 0.83; 95% CI, 0.6 to 1.14); however, GLP-1s were associated with a statistically significant decrease in dementia (OR, 0.55; 95% CI, 0.35 to 0.86) whereas SGLT2is were not (OR, 1.2; 95% CI, 0.67 to 2.17). According to the authors, the larger risk reduction observed with GLP-1s could potentially be attributed to differences in populations enrolled, as there was a higher all-cause dementia event rate in the control group of GLP-1 trials compared with SGLT2i trials (0.14% versus 0.05%) which led to an increase in statistical power to detect associations.  

The content in this publication is not a substitute for professional medical advice. For questions regarding any medical condition or if you need medical advice, please contact your health care provider. 

All brand names are property of their respective owners. 

Login Portals
Compliance / Legal
Careers
© 2025 Prime Therapeutics LLC